SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-164916
Filing Date
2020-06-10
Accepted
2020-06-09 21:21:17
Documents
18
Period of Report
2020-06-08
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d941680d8k.htm   iXBRL 8-K 40127
2 EX-1.1 d941680dex11.htm EX-1.1 253850
3 EX-5.1 d941680dex51.htm EX-5.1 5905
4 EX-99.1 d941680dex991.htm EX-99.1 9381
5 EX-99.2 d941680dex992.htm EX-99.2 11000
9 GRAPHIC g941680logo.jpg GRAPHIC 9040
10 GRAPHIC g941680logo1.jpg GRAPHIC 11842
  Complete submission text file 0001193125-20-164916.txt   554197

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA fate-20200608.xsd EX-101.SCH 3093
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE fate-20200608_lab.xml EX-101.LAB 18138
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fate-20200608_pre.xml EX-101.PRE 11423
13 EXTRACTED XBRL INSTANCE DOCUMENT d941680d8k_htm.xml XML 3402
Mailing Address 3535 GENERAL ATOMICS COURT SUITE 200 SAN DIEGO CA 92121
Business Address 3535 GENERAL ATOMICS COURT SUITE 200 SAN DIEGO CA 92121 858.875.1803
FATE THERAPEUTICS INC (Filer) CIK: 0001434316 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36076 | Film No.: 20953351
SIC: 2836 Biological Products, (No Diagnostic Substances)